SuperSpectra develops a noninvasive imaging device for the early detection and degradation followup of Alzheimer's disease by measuring CSF A and tau quantitative results.The company offers a high-accuracy quantitative measurement with real-time imaging of biomarkers of Alzheimer's disease.

This noninvasive direct CSF analysis is ionizing radiation free, pain free, and risk free.

Tests can be performed daily/weekly.